Lukas biomedical Inc.(TW:6814)
NT$17.60+0.10 (+0.57%)
TW:6814
Lukas biomedical Inc. financials statements
NT$17.60
At close:+0.10 (+0.57%)
Lukas biomedical Inc. (6814) Ratios
Lukas biomedical Inc. Ratios
TW:6814's free cash flow for Q2 2026 was NT$-45.57M. For the 2026 fiscal year, TW:6814's free cash flow was decreased by NT$-1.11M and operating cash flow was NT$-44.46M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.80 | 2.19 | 1.52 | 1.87 | 0.92 |
| Quick Ratio | 0.50 | 1.52 | 0.88 | 1.12 | 0.72 |
| Cash Ratio | 0.30 | 1.14 | 0.55 | 0.71 | 0.50 |
| Solvency Ratio | -0.32 | -0.44 | -0.10 | -0.09 | -0.03 |
| Operating Cash Flow Ratio | -0.54 | -1.24 | -0.20 | -0.13 | -0.12 |
| Short-Term Operating Cash Flow Coverage | -0.80 | -6.17 | -0.93 | -1.13 | -0.17 |
| Net Current Asset Value | NT$ -94.29M | NT$ -26.19M | NT$ -73.69M | NT$ -46.65M | NT$ -124.04M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.37 | 0.24 | 0.29 | 0.23 | 0.42 |
| Debt-to-Equity Ratio | 0.65 | 0.35 | 0.45 | 0.34 | 0.77 |
| Debt-to-Capital Ratio | 0.39 | 0.26 | 0.31 | 0.26 | 0.44 |
| Long-Term Debt-to-Capital Ratio | 0.16 | 0.15 | 0.20 | 0.15 | 0.18 |
| Financial Leverage Ratio | 1.78 | 1.46 | 1.57 | 1.46 | 1.85 |
| Debt Service Coverage Ratio | -0.73 | -4.34 | -0.80 | -1.17 | -0.02 |
| Interest Coverage Ratio | -25.28 | -30.31 | -14.18 | -16.60 | -9.75 |
| Debt to Market Cap | 0.10 | 0.06 | 0.08 | 0.05 | 0.12 |
| Interest Debt Per Share | 3.80 | 2.99 | 3.50 | 3.12 | 6.83 |
| Net Debt to EBITDA | -2.16 | -0.80 | -7.48 | -6.60 | -433.96 |
| Profitability Margins | |||||
| Gross Profit Margin | 53.31% | 59.59% | 57.75% | 52.98% | 60.95% |
| EBIT Margin | -45.22% | -48.17% | -19.07% | -25.43% | -27.55% |
| EBITDA Margin | -31.27% | -33.12% | -5.42% | -5.92% | -0.23% |
| Operating Profit Margin | -45.22% | -48.54% | -18.79% | -26.23% | -27.32% |
| Pretax Profit Margin | -46.67% | -49.77% | -20.39% | -27.01% | -30.35% |
| Net Profit Margin | -47.71% | -49.72% | -20.43% | -27.10% | -31.40% |
| Continuous Operations Profit Margin | -47.71% | -49.72% | -20.43% | -27.10% | -31.40% |
| Net Income Per EBT | 102.23% | 99.90% | 100.16% | 100.30% | 103.47% |
| EBT Per EBIT | 103.21% | 102.54% | 108.53% | 103.00% | 111.07% |
| Return on Assets (ROA) | -20.06% | -19.81% | -10.73% | -10.44% | -9.32% |
| Return on Equity (ROE) | -35.65% | -28.97% | -16.90% | -15.29% | -17.26% |
| Return on Capital Employed (ROCE) | -26.01% | -21.96% | -11.36% | -11.45% | -10.75% |
| Return on Invested Capital (ROIC) | -20.30% | -20.71% | -10.64% | -10.95% | -8.43% |
| Return on Tangible Assets | -20.08% | -19.81% | -10.73% | -10.44% | -9.32% |
| Earnings Yield | -6.60% | -7.99% | -4.48% | -4.30% | -3.58% |
| Efficiency Ratios | |||||
| Receivables Turnover | 15.58 | 19.61 | 21.71 | 15.29 | 8.63 |
| Payables Turnover | 20.38 | 13.45 | 14.09 | 9.89 | 20.39 |
| Inventory Turnover | 2.37 | 2.02 | 2.67 | 2.05 | 2.29 |
| Fixed Asset Turnover | 3.55 | 3.43 | 4.62 | 2.73 | 1.80 |
| Asset Turnover | 0.42 | 0.40 | 0.53 | 0.39 | 0.30 |
| Working Capital Turnover Ratio | 7.96 | 3.90 | 5.88 | 9.46 | -10.89 |
| Cash Conversion Cycle | 159.65 | 172.37 | 127.76 | 165.09 | 183.82 |
| Days of Sales Outstanding | 23.42 | 18.61 | 16.81 | 23.87 | 42.27 |
| Days of Inventory Outstanding | 154.13 | 180.91 | 136.86 | 178.14 | 159.45 |
| Days of Payables Outstanding | 17.91 | 27.14 | 25.91 | 36.92 | 17.90 |
| Operating Cycle | 177.55 | 199.52 | 153.67 | 202.01 | 201.73 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.47 | -1.78 | -0.32 | -0.20 | -0.49 |
| Free Cash Flow Per Share | -1.67 | -1.95 | -0.39 | -0.28 | -0.79 |
| Dividend Paid and CapEx Coverage Ratio | -7.21 | -10.35 | -4.42 | -2.50 | -1.61 |
| Capital Expenditure Coverage Ratio | -7.21 | -10.35 | -4.42 | -2.50 | -1.61 |
| Operating Cash Flow Coverage Ratio | -0.39 | -0.61 | -0.09 | -0.07 | -0.07 |
| Operating Cash Flow to Sales Ratio | -0.34 | -0.37 | -0.05 | -0.04 | -0.10 |
| Free Cash Flow Yield | -5.39% | -6.55% | -1.36% | -0.89% | -1.89% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -15.20 | -12.54 | -22.38 | -23.33 | -27.87 |
| Price-to-Sales (P/S) Ratio | 7.23 | 6.22 | 4.56 | 6.31 | 8.77 |
| Price-to-Book (P/B) Ratio | 5.40 | 3.63 | 3.77 | 3.56 | 4.82 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -18.56 | -15.27 | -73.33 | -111.95 | -52.81 |
| Price-to-Operating Cash Flow Ratio | -21.13 | -16.75 | -89.93 | -156.76 | -85.59 |
| Price-to-Earnings Growth (PEG) Ratio | 1.06 | -0.15 | 4.32 | 2.33 | -0.08 |
| Enterprise Value Multiple | -25.29 | -19.59 | -91.52 | -113.23 | -4264.27 |
| Enterprise Value | 1.42B | 1.23B | 1.15B | 1.24B | 1.54B |
| EV to EBITDA | -25.29 | -19.59 | -91.52 | -113.23 | -4264.27 |
| EV to Sales | 7.91 | 6.49 | 4.96 | 6.70 | 9.77 |
| EV to Free Cash Flow | -20.29 | -15.93 | -79.86 | -118.88 | -58.79 |
| EV to Operating Cash Flow | -23.11 | -17.47 | -97.94 | -166.46 | -95.28 |
| Tangible Book Value Per Share | 5.73 | 8.23 | 7.60 | 8.85 | 8.66 |
| Shareholders’ Equity Per Share | 5.74 | 8.23 | 7.60 | 8.85 | 8.67 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.02 | 0.00 | -0.00 | -0.00 | -0.03 |
| Revenue Per Share | 4.29 | 4.80 | 6.29 | 4.99 | 4.76 |
| Net Income Per Share | -2.05 | -2.38 | -1.28 | -1.35 | -1.50 |
| Tax Burden | 1.02 | 1.00 | 1.00 | 1.00 | 1.03 |
| Interest Burden | 1.03 | 1.03 | 1.07 | 1.06 | 1.10 |
| Research & Development to Revenue | 0.46 | 0.50 | 0.33 | 0.30 | 0.35 |
| SG&A to Revenue | 0.52 | 0.58 | 0.43 | 0.49 | 0.54 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.73 | 0.75 | 0.25 | 0.15 | 0.33 |
Currency in TWD
